Ocular and systemic pharmacokinetics of latanoprost in humans

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages S6-

  Sjöquist, Birgitta ^a   Stjernschantz, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Latanoprost; Metabolism; Ocular pharmacokinetics; Systemic pharmacokinetics

Indexed keywords

1,2 DINORLATANOPROST ACID; 1,2,3,4 TETRANORLATANOPROST ACID; DRUG METABOLITE; LATANOPROST; LATANOPROST ACID; UNCLASSIFIED DRUG;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG URINE LEVEL; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOASSAY;

EID: 0036669793     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00302-8     Document Type: Article

References (17)

1. 13-reductase in porcine cornea. Acta Chem Scand. 46:1992;108-110.
2. Basu S., Sjöquist B., Stjernschantz J., Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukotrienes Essential Fatty Acids. 50:1994;161-168.
3. Basu S., Sjöquist B. Development of a radioimmunoassay for latanoprost and its application in a long-term study in monkeys. Prostaglandins Leukotrienes Essential Fatty Acids. 55:1996;427-432.
4. Bito L.Z. Accumulation and apparent active transport of prostaglandins by some rabbit tissues in vitro. J Physiol (London). 221:1972;371-387.
5. Bito L.Z., Salvador E.V. Intraocular fluid dynamics. III. The site and mechanism of prostaglandin transfer across the blood intraocular fluid barriers. Exp Eye Res. 14:1972;233-241.
6. 2α analog, PhXA41 (latanoprost), for glaucoma management. J Lipid Mediators. 6:1993;535-543.
7. 2α metabolism by human ocular tissues. Inv Ophthalmol Vis Sci. 31:1990;1389-1394.
8. 1 by ocular tissues in vitro. Exp Eye Res. 19:1974;141-146.
9. Goh Y., Urade Y., Fujimoto N., Hayashi O. Content and formation of prostaglandins and distribution of prostaglandin-related enzyme activities in the rat ocular system. Biochim Biophys Acta. 921:1987;302-309.
10. Resul B., Stjernschantz J., No K., Liljebris C.et al. Phenyl-substituted prostaglandins. potent and selective antiglaucoma agents J Med Chem. 36:1993;243-248.
11. Schuster V.L., Lu R., Coca-Prados M. The prostaglandin transporter is widely expressed in ocular tissues. Surv Ophthalmol. 41(Suppl 2):1997;S41-S45.
12. Sjöquist B., Basu S., Byding P.et al. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Disp. 26:1998;745-754.
13. Sjöquist B., Tajallaei S., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication. Single intravenous, oral or topical administration on the eye Arzneimittelforschung. 49:1999;225-233.
14. Sjöquist B., Uhlin A., Byding P., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication. Repeated topical administration on the eye Arzneimittelforschung. 49:1999;234-239.
15. Sjöquist B., Johansson A., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication. Tissue distribution after topical administration on the eye studied by whole body autoradiography Arzneimittelforschung. 49:1999;240-249.
16. Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogues for glaucoma treatment. Drugs Future. 17:1992;691-704.
17. Stjernschantz J., Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 7:1996;11-17.